Misuse of March-In Authority Could Jeopardize Progress in Cancer Research and Prove Ineffective in Intent to Lower Prescription Drug Prices
Today, the American Cancer Society Cancer Action Network (ACS CAN) issued a letter to the National Institutes of Standards and Technology (NIST) commenting on the utilization of march-in rights (MIR) to lower prescription drug costs following the release of new guidance by the administration on its application.